絞り込み

16424

広告

943件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Safety and timing of resuming dabigatran after major gastrointestinal bleeding reversed by idarucizumab.

Reversal agents for non-vitamin K antagonist oral anticoagulants.

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation?

Comparison of anticoagulant therapy for atrial fibrillation - novel oral anticoagulants versus vitamin K antagonists.

Stroke Prevention in Atrial Fibrillation - Which is the BEST?: Balanced in Efficacy and Safety as a Thromboprophylactic.

Prothrombin times in the presence of edoxaban - in-vivo experience from King's College hospital.

Direct oral anticoagulants and its implications in dentistry. A review of literature.

Direct oral anticoagulants: An update.

Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures.

[Clinico-Pharmacological and Clinical Basis of Multiplicity of Intake of Novel Oral Anticoagulants].

Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study.

Superior mesenteric vein thrombosis treated with edoxaban.

[Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]

The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations.

Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.

Comparison of Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Multicriteria Decision Analysis.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.

Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります